Artivion (AORT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
The annual meeting will be held virtually on May 12, 2026, with voting on director elections, executive compensation, and auditor ratification.
Shareholders of record as of March 16, 2026, are eligible to vote; a majority of shares constitutes a quorum.
The Board recommends voting for all director nominees, executive compensation, and auditor ratification.
Proxy materials and the 2025 Annual Report are available online and by request.
Voting matters and shareholder proposals
Nine directors are nominated for election to serve until the next annual meeting.
Advisory (non-binding) vote on executive compensation (Say-on-Pay) is included.
Ratification of Ernst & Young LLP as independent auditor for fiscal 2026 is proposed.
Shareholder proposals for the 2027 meeting must be submitted by December 2, 2026, for inclusion.
Board of directors and corporate governance
Board consists of nine members, with 22.2% female and 11.1% racial diversity; average tenure is 11.5 years.
Eight of nine directors are independent under NYSE standards; CEO serves as Chairman.
Four standing committees: Audit, Compensation, Corporate Governance, and Innovation & Healthcare Compliance.
Lead Independent Director role fosters board independence; committee charters and governance documents are available online.
Latest events from Artivion
- Q3 2024 revenue up 10% and EBITDA up 28%, led by product and global expansion.AORT
Q3 20249 Jul 2026 - Q1 revenue up 4% with strong product growth; guidance raised despite cyber-related headwinds.AORT
Q1 20259 Jul 2026 - Double-digit revenue and EBITDA growth expected in 2025, driven by innovation and global expansion.AORT
Q4 20248 Jul 2026 - Aortic-focused innovation and strong execution drive double-digit growth and margin expansion.AORT
Stifel 2025 Healthcare Conference8 Jul 2026 - AMDS and NEXUS launches drive growth in a $2B global aortic arch market.AORT
Truist Securities MedTech Conference 202616 Jun 2026 - Q1 2026 revenue up 18% to $116.3M; Endospan acquisition and NEXUS approval drive future growth.AORT
Q1 20268 May 2026 - Double-digit growth driven by On-X valves, stent grafts, and strong clinical outcomes.AORT
Corporate presentation8 May 2026 - Strong 2025 growth and robust 2026 outlook with double-digit revenue and EBITDA gains projected.AORT
Q4 202515 Apr 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.AORT
Proxy filing1 Apr 2026